Occurrence of a novel t(11;19)(q13;q13.3) in complete remission of acute promyelocytic leukemia.

Abstract

A woman with t(15;17) and PML/RAR alpha positive acute promyelocytic leukemia (APL-M3v) achieved a complete remission (CR) with cytogenetic and molecular conversion, after one-month ATRA plus idarubicin treatment. During CR, less than one-month after consolidation therapy with topoisomerase II inhibitors, a novel t(11;19) (q13;q13.3) was detected in peripheral blood stem cells and later in harvest bone marrow cells. Persisting CR and the negativity for BCL1 and PRAD1 genes rearrangement, the autotransplantation was performed, with good outcome. The patient is still in CR eighteen months post-transplant, in spite of the persistence of a small t(11;19) clone in BM cells. The emergence of a novel chromosomal change during CR of acute leukemia is a rare phenomenon. This is the first t(11;19)(q13;q13.3) described in APL. This finding raises the issue of whether the abnormal karyotypes at remission might represent a risk of tumor recurrence. The meaning of this genomic instability is yet unknown.

• Authors: P Temperani, M Luppi, F Giacobbi, P Vaccari, G Longo, A Donelli, F Narni, G Torelli, G Emilia
• Journal: Cancer genetics and cytogenetics (Cancer Genet Cytogenet) Vol. 101 Issue 1 Pg. 35-8 (Feb 1998) ISSN: 0165-4608 [Print] United States
• PMID: 9460497 (Publication Type: Case Reports, Journal Article, Research Support, Non-U.S. Gov't)

Chemical References

• Antineoplastic Agents
• Tretinoin
• Idarubicin

Topics

• Antineoplastic Agents (therapeutic use)
• Chromosome Banding
• Chromosomes, Human, Pair 11
• Chromosomes, Human, Pair 19
• Female
• Humans
• Idarubicin (therapeutic use)
• In Situ Hybridization, Fluorescence
• Leukemia, Promyelocytic, Acute
• Middle Aged
• Translocation, Genetic
• Tretinoin (therapeutic use)